~~<i id='BB9506F54E'><strike id='BB9506F54E'><tt id='BB9506F54E'><pre id='BB9506F54E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：fashion 2025-10-01 21:36:05 - browse：84

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： What does generative AI mean for health care? We asked experts

explore

hotspot

Wikipedia

focus

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

WSS

Hearing on Medicare drug price negotiation gets unusually heated

Senate HELP committee spars over health care workforce policies

Psychedelics group wrestles with new pharma identity

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Why are Kaiser Permanente staff considering a strike?

Duchenne breakthrough therapy leaves behind pioneering families

focus

fashion

explore

In age of alternative facts, a scholarly course on calling out crap

Jerome Adams on the need for new antivirals for Covid

After affirmative action ruling, medical educators look to 'holistic review'

Apple is now the first public company to be valued at $3 trillion

Virginia high school admissions case could be legal follow

Psychedelics group wrestles with new pharma identity

Medical records are filled with copy

23andMe had bad news about my health. I wish a person had delivered it

Dobbs anniversary: the lost opportunity of abortion as health care

Changes to biosimilar regulatory framework must prioritize patients

hotspot

Ukraine and a new approach to mental health in war

What Congress can do to address the rural doctor shortage

Alkermes shareholders re

Second xenotransplant done with gene

Medical student insurance fails on mental health care coverage

Psychedelics group wrestles with new pharma identity

hotspot

Wikipedia

Wikipedia

focus